{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=23",
    "query": {
      "intervention": "cetuximab",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 559,
    "total_pages": 56,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T02:27:26.170Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04587128",
      "title": "Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Panitumumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI Protocol",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2020-10-19",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04587128"
    },
    {
      "nct_id": "NCT00725400",
      "title": "Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cetuximab and Radiation Therapy",
          "type": "OTHER"
        },
        {
          "name": "Surgery and Radiation Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "American Scitech International",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2010-02",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2011-07-20",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 1,
      "location_summary": "Englishtown, New Jersey",
      "locations": [
        {
          "city": "Englishtown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00725400"
    },
    {
      "nct_id": "NCT01637194",
      "title": "Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Colon Cancer",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity",
        "Stage IVA Colon Cancer",
        "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Colon Cancer",
        "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Salivary Gland Cancer",
        "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Tongue Cancer"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2008-11",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-11",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01637194"
    },
    {
      "nct_id": "NCT06102902",
      "title": "Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Adenocarcinoma",
        "Recurrent Colorectal Adenocarcinoma",
        "Refractory Colorectal Adenocarcinoma",
        "Stage IV Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "BET Bromodomain Inhibitor ZEN-3694",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-06-05",
      "completion_date": "2027-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 16,
      "location_summary": "Costa Mesa, California • Irvine, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06102902"
    },
    {
      "nct_id": "NCT00081302",
      "title": "Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-03",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2015-11-17",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 1,
      "location_summary": "Arlington, Texas",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081302"
    },
    {
      "nct_id": "NCT01280643",
      "title": "Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "nucleic acid sequencing",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2010-03",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-15",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280643"
    },
    {
      "nct_id": "NCT05249426",
      "title": "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma (HNSCC)"
      ],
      "interventions": [
        {
          "name": "BI 765063",
          "type": "DRUG"
        },
        {
          "name": "Ezabenlimab",
          "type": "DRUG"
        },
        {
          "name": "BI 836880",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Investigator´s Choice Chemotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2022-04-12",
      "completion_date": "2026-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05249426"
    },
    {
      "nct_id": "NCT00079274",
      "title": "Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adenocarcinoma of the Colon",
        "Stage III Colon Cancer"
      ],
      "interventions": [
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Locally Directed Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 3397,
      "start_date": "2004-02",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 858,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 538 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079274"
    },
    {
      "nct_id": "NCT01081808",
      "title": "Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Tumors",
        "Solid Tumors",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "EGFRBi-armed autologous activated T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Roger Williams Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2009-10",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-03-25",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01081808"
    },
    {
      "nct_id": "NCT01696955",
      "title": "Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Recurrent Head and Neck Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Tivantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2012-08-20",
      "completion_date": "2017-05-05",
      "has_results": true,
      "last_update_posted_date": "2018-12-19",
      "last_synced_at": "2026-10-29T02:27:26.170Z",
      "location_count": 24,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696955"
    }
  ]
}